AEON Biopharma posts corporate presentation; details limited

AEON Biopharma, Inc.

Presentation made available on IR website on March 10, 2025.
Focus on PrabotulinumtoxinA as a potential biosimilar for therapeutic indications.
No specific financial, clinical, or operational data disclosed in the filing.

item 7.01 item 9.01

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.